| Identification | Back Directory | [Name]
TAK-788 | [CAS]
1847461-43-1 | [Synonyms]
TAK-788
AP 32788
Mobocertinib
Mobocertinib (TAK788)
AP32788, MOBOCERTINIB
Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate
5-Pyrimidinecarboxylic acid, 2-[[4-[[2-(dimethylamino)ethyl]methylamino]-2-methoxy-5-[(1-oxo-2-propen-1-yl)amino]phenyl]amino]-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester | [Molecular Formula]
C32H39N7O4 | [MDL Number]
MFCD32669806 | [MOL File]
1847461-43-1.mol | [Molecular Weight]
585.71 |
| Hazard Information | Back Directory | [Uses]
Mobocertinib (TAK-788,1847461-43-1) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib effectively inhibits oncogenic variants containing mutations that activate the EGFRex20ins, with selectivity superior to that of wild-type EGFR. Mobocertinib is FDA-approved for the treatment of patients with non-small cell lung cancer (NSCLC) who have a HER2 mutation or an EGFR mutation, including an exon 20 insertion mutation. Mobocertinib is approved by the FDA for the treatment of patients with non-small cell lung cancer (NSCLC) who have HER2 mutations or EGFR mutations, including exon 20 insertion mutations.
|
|
|